Similar articles

• Re-engineering drug discovery and development.

  FitzGerald GA. FitzGerald GA. LDI Issue Brief. 2011 Oct;17(2):1-4. LDI Issue Brief. 2011. PMID: 22049582
• Biotech R&D still reeling.

  Lawrence S. Lawrence S. Nat Biotechnol. 2004 Sep;22(9):1068. doi: 10.1038/nbt0904-1068. Nat Biotechnol. 2004. PMID: 15340460 No abstract available.
• Public-private partnerships in drug development for underdeveloped countries: an interview with Craig Wheeler, President of Chiron's Biopharmaceutical Division. Interview by Thomasine Kushner.

  Wheeler C. Wheeler C. Camb Q Healthc Ethics. 2003 Fall;12(4):429-33. Camb Q Healthc Ethics. 2003. PMID: 14619375 No abstract available.
• The interface between publicly funded and industry-funded research in pediatric psychopharmacology: opportunities for integration and collaboration.

  Vitiello B, Heiligenstein JH, Riddle MA, Greenhill LL, Fegert JM. Vitiello B, et al. Biol Psychiatry. 2004 Jul 1;56(1):3-9. doi: 10.1016/j.biopsych.2004.03.011. Biol Psychiatry. 2004. PMID: 15219466 Review.
• Outlook: finding improved medicines: the role of academic-industrial collaboration.

  Chin-Dusting J, Mizrahi J, Jennings G, Fitzgerald D. Chin-Dusting J, et al. Nat Rev Drug Discov. 2005 Nov;4(11):891-7. doi: 10.1038/nrd1879. Nat Rev Drug Discov. 2005. PMID: 16247439 Review.